文献速递核素与放射性配体治疗

建立神经内分泌肿瘤中177Lu-DOTATATE的体外剂量学模型与剂量-效应关系

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2025-08-01

本研究以GOT1和NCI-H69肿瘤细胞系比较肽受体放射性核素治疗(PRRT)与外照射放疗(EBRT)的放射生物学效应,并建立基于影像的多细胞剂量学模型。结果显示传统剂量学在培养板设置中可低估吸收剂量达90%,PRRT相对生物效应最高为NCI-H69细胞0.43±0.07、GOT1细胞0.22±0.02。结论认为PRRT在体外需平均3倍于EBRT的吸收剂量才能达到等效效应。

要点

  • 传统剂量学在培养板设置中可低估吸收剂量达90%,并忽略剂量异质性。
  • PRRT相对生物效应最高为NCI-H69细胞0.43±0.07、GOT1细胞0.22±0.02。
  • PRRT在体外需平均3倍于EBRT的吸收剂量才能达到等效效应。

核心结论

  • PRRT在体外需平均3倍于EBRT的吸收剂量才能达到等效效应。
  • 传统剂量学通过低估吸收剂量而高估相对生物效应。

研究设计与样本

  • 比较GOT1和NCI-H69肿瘤细胞系对PRRT与EBRT的放射生物学反应。
  • 评估7天存活率和多个时间点的细胞死亡。
  • 建立基于影像的多细胞剂量学模型以反映体外暴露复杂性,并与传统方法比较。

主要发现

  • 悬浮状态下PRRT吸收剂量在孵育期间以培养基为主,孵育后在小型细胞簇内以交叉剂量为主。
  • 传统剂量学在培养板设置中可低估吸收剂量达90%,并忽略剂量异质性。
  • 初始剂量率根据细胞簇大小和细胞排列不同可相差达2.3倍。
  • 7天存活率丢失的PRRT相对EBRT最大相对生物效应为NCI-H69细胞0.43±0.07、GOT1细胞0.22±0.02。
  • NCI-H69细胞对PRRT诱导的细胞死亡抵抗强于EBRT,而GOT1细胞两种处理的细胞死亡水平相似但剂量-反应动态不同。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study investigates the radiobiology of peptide receptor radionuclide therapy (PRRT) using clinically relevant cancer cell lines by developing a framework for realistic cellular dosimetry in 2- and 3-dimensional cluster-forming configurations. Methods: The radiobiologic responses of GOT1 and NCI-H69 tumor cell lines to PRRT and external beam radiotherapy (EBRT) were compared. Viability at 7 d and cell death at multiple time points were assessed. Image-based multicellular dosimetry models were developed to reflect in vitro exposure complexity and were compared with traditional approaches. Results: The PRRT absorbed dose in suspension was dominated by medium during incubation and by a cross-dose within small clusters after incubation. Our findings reveal that traditional dosimetry can underestimate absorbed doses by up to 90% in plated setups and overlooks dose heterogeneity, with initial dose rates varying by up to 2.3-fold based on cluster size and cell arrangement. The maximum relative biologic effectiveness of PRRT compared with EBRT for loss of viability at 7 d was 0.43 ± 0.07 for NCI-H69 cells and 0.22 ± 0.02 for GOT1 cells. NCI-H69 cells showed greater resistance to PRRT-induced cell death than to EBRT, whereas GOT1 cells exhibited similar cell death levels for both treatments, albeit with different dose-response dynamics. Conclusion: PRRT requires on average an absorbed dose 3 times higher than EBRT to achieve equivalent effects in vitro. Traditional dosimetry overestimates the relative biologic effectiveness by underestimating the absorbed dose.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tamborino G, Engbers P, de Wolf TH, et al. Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med. 2025. PMID: 40404397. doi:10.2967/jnumed.125.269470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。